INTRODUCTION

Primary Biliary Cirrhosis (PBC) results from T-cell induced damage to intra-hepatic biliary channels leading to inflammation and cholestasis. PBC was introduced by Addison et al in 1851. It was named PBC by Ahrens et al in 1950. Walker et al explained the correlation between AMA seropositivity and PBC.

The disease appears to be autoimmune in nature because of the observation of immunological symptoms and phenomena occurring in patients with PBC. It is this autoimmunity that leads to destruction of microscopic biliary channels. The destruction is progressive and usually permanent. PBC is diagnosed by the presence of cholestatic blood picture, antimitochondrial antibodies (AMA), and specific liver biopsy findings. The current article reviews epidemiology, pathophysiology, clinical features, diagnosis and management of PBC, and also explains the relatively new term of AMA-negative PBC. The article also reviews Overlap Syndromes which are the presence of two autoimmune liver conditions in a single liver.

MATERIAL AND METHODS

Articles published over a span of 48 years extending from 1968 to 2016 were studied for writing the present review. Keywords comprising Primary Biliary Cirrhosis, Anti-mitochondrial antibody, cholestatic liver disease, AMA-negative primary biliary cirrhosis and Overlap Syndromes were used as search words on search engines including Google Scholar, PubMed, iMediSearch, MedConnect, Medicine, Medline, MDLinx and Medscape. Data gathered from these articles was reviewed and given the shape of current article.

EPIDEMIOLOGY

PBC has a female predominance (upto 80%) between 30th and 65th years of life. 5-10% of the patients are men. It has a prevalence of 65 per 100,000 and 12 per 100,000 in female and male populations respectively. The incidence is 5 per 100,000 for females and 1 per 100,000 for males.

PATHOPHYSIOLOGY

An array of multiple factors comes into play considering the pathophysiology of PBC.

1. Genetic Factors:

PBC is prevalent in immediate relatives of patients...
Primary biliary cirrhosis

with PBC thereby implying that it may be inher-itable11. Among all the autoimmune diseases, it has the maximum reported concordance rate (62.5%) in monozygotic twins12.

2. Environmental Factors:
Viruses, bacteria (Novosphingobium aromaticicivorans, Chlamyphilia pneumoniae; urinary tract infections (UTIs) from E.coli or Lactobacillus delbrueckii), smoking, possible use of Hormone Replacement Therapy (HRT) and chemicals (hair dye) may induce molecular mimicry which results in production of antibodies and clinical progression of PBC13,14,15.

3. Immunologic Factors:
Though the exact mechanism is unknown, but it is postulated that unstable lymphocytic DNA may also be responsible for the causation of PBC16.

4. Biliary Factors:
Changes in the formulation of bile acid and bile fluid in PBC patients suggest that transporter proteins may be involved in the development of PBC17. It is believed that biliary epithelium is protected by bicarbonate rich bile18.

ASSOCIATIONS OF PBC
Being an autoimmune condition, PBC has been found to be related to a myriad of other autoimmune diseases19. These include: Dry gland ‘sicca’ syndrome, Sjogren’s syndrome, Rheumatoid arthritis (RA), Autoimmune thyroid disease, Renal tubular acidosis (RTA), Mixed connective tissue disease (MCTD), Polymyositis, Polymyalgia Rheumatica (PMR), Pulmonary fibrosis, CREST (calcinosi, Raynaud’s syndrome, esophageal dysmotility, sclerodactyly, telangietasias) syndrome, Systemic lupus erythematosus (SLE), Pernicious anemia, Ulcerative colitis (UC), Exogenous pancreatic insufficiency, and Myasthenia gravis (MG)20,21,22,23,24.

CLINICAL FEATURES
PBC initially presents with fatigue, and this may be the only complaint of the patient for quite a long time before the other symptoms set in25. Patients may also complain of pruritis. Jaundice is usually evident later. Other complaints include right hypochondrium pain from hepatomegaly, splenomegaly, and steatorrhea due to fat malabsorption. Excoriations may be visible on skin from continuous itching. Xanthelasmas, xanthomas and skin hyper-pigmentation also occur26. Low bone density, osteoporosis and fractures occur due to vitamin D malabsorption27. Patients may also develop features of decompensated liver disease manifested as ascites, bleeding from esophageal varices, and encephalopathy25. Xerophthalmia and xerostomia may be seen if other autoimmune conditions co-exist with PBC28.

DIAGNOSTIC PRINCIPLES
PBC is suspected when both cholestasis and cirrhosis (which occurs over a course of years or decades) are present in middle-aged women29. Alkaline phosphatase, gamma glutamyl transferase and serum bilirubin are elevated30. Levels of immunoglobulin M and high density lipoprotein (HDL) are also raised31. Abdominal ultrasound scan needs to be done to rule out mechanical obstruction either intra-hepatic or extra-hepatic as the cause of cholestatic picture evident on biochemistry.

Anti-mitochondrial antibodies (AMA) are present in 95% of the patients with PBC. They are formed against the E2 subunit of pyruvate dehydrogenase (PDH-E2) which in itself is a member of the inner mitochondrial membrane-expressed oxoacid dehydrogenase complex32. PBC-specific AMA can be detected by immunofluorescence testing, ELISA and Western Blot Analyses; this excludes drug-induced and infectious causes of AMA-positivity33,34,35,36. Antinuclear autoantibodies (ANA) are commonly present in PBC patients in nuclear rim or nuclear dot pattern37.

ANTI-MITOCHONDRIAL ANTIBODIES (AMA) NEGATIVE PBC
A small sub-set of patients with PBC is AMA-negative38,39,40. These patients share similar clinical, biochemical, and histologic features of PBC with those who are AMA-positive41. This AMA-negative PBC is also known as Autoimmune cholangitis (AIC)15. In these patients, a biopsy is indicated for confirmation of PBC; in the presence of AMA, biopsy is done to stage cirrhosis and is usually not mandatory for diagnosis29,32. Prior to the introduction of the sensitive ELISA testing and immunoblotting, 10-15% of patients with PBC were AMA-negative; at present only 5-10% are AMA-negative41,42.

There is some debate as to whether autoimmune cholangitis (AIC), AMA-negative PBC, and classic PBC are one and the same thing. AIC cannot be incorporated into a single diagnostic category. It may represent variant shapes of different autoimmune liver diseases, an evolution stage between two autoimmune disorders, or a separate entity with varying manifestations43.

Lacerda MA and colleagues44 reported 20 patients who had AMA-negative PBC compared with 20 AMA-positive controls. There was no remarkable difference with respect to clinical features, and associated autoimmune phenomena at the time of diagnosis. The immunoglobulin levels and liver profile were also not
THERAPEUTIC PRINCIPLES

1. **URSODEOXYCHOLIC ACID (UDCA):**

   This is the only medical treatment approved by FDA for PBC. The therapeutic dose in PBC is 15mg/kg body weight per day. It brings about an improvement in liver and immunological profile, histology and also improves chances of survival, but no effect has been seen on fatigue and osteoporosis. It is an immuno-modulator, that alters cell signal transduction and also modifies biliary hydrophilicity. The drug is very effective in stages I and II of PBC, in which the survival is similar to that of healthy controls. It is not indicated in severe cholestasis and first trimester of pregnancy.

   Weight gain and loose stools are the reported side effects. Currently it has no therapeutic alternative.

**IMMUNOSUPPRESSION IN PBC**

Immunosuppression has generally been disappointing in treatment of PBC.

1. **CORTICOSTEROIDS:**

   Treatment with steroids can improve liver biochemistry, and raised immunoglobulin levels. No significant improvement of bilirubin, pruritis or histology has been noticed with corticosteroid therapy. Budesonide may cause improvement in liver histopathology but leads to worsening of bone density.

2. **AZATHIOPRINE:**

   It has not been proven to be as effective in PBC, as in autoimmune hepatitis.

3. **CYCLOSPORIN A:**

   Cyclosporin is a classic transplant immunosuppressant. In a study carried out in 346 patients, it did not show any significant effects on histopathological progression.

4. **D-PENICILLAMINE:**

   Because copper accumulates in biliary channels in PBC, d-penicillamine can be given on a trial basis as a copper chelator. It is an immunosuppressive and anti-fibrotic drug.

5. **COLCHICINE:**

   It has anti-inflammatory and anti-fibrotic properties. Though improvement occurs in liver biochemical and synthetic functions, a remarkable difference in clinical features and histopathology has not been observed with colchicine.

6. **METHOTREXATE:**

   In a dose of 15mg/week it leads to improvement of biochemical parameters except bilirubin.
Primary biliary cirrhosis

OTHER DRUGS UNDER TRIAL

Mycophenolate mofetil, tacrolimus and monoclonal antibodies against interleukin-2 receptor are also being investigated as possible alternative therapies for refractory cases of PBC64,65.

THERAPY IN NON-RESPONDERS

Non-responders may be treated with a combination of ursodeoxycholic acid with steroids, sulindac, colchicine or methotrexate66.

SYMPTOMATIC TREATMENT OF COMPLICATIONS67

1. Pruritis can be managed with cholestyramine, rifampicin, opioid antagonists, and serotonin antagonists. Resistant cases may be treated with plasmapheresis.
2. Ascites can be treated conservatively with diuretics, and beta blockers to control portal HTN.
3. Osteoporosis can be managed with vitamin D and calcium supplementation, and bisphosphonates.
4. Bleeding esophageal varices require endoscopic intervention in the form of band ligation or sclerotherapy.
5. Fat-soluble vitamin supplementation is necessary to cover up for deficiencies of fat soluble vitamins. Deficiencies are aggravated when cholestyramine is administered.
6. Modafinil is given for daytime somnolence associated with PBC.

LIVER TRANSPLANTATION

This is the definitive treatment for PBC-induced liver failure. Fatigue may not be reversed by liver transplantation68. Ten-year survival rates after liver transplantation are 75-80% and recurrence of PBC occurs in 10-40% of the patients after transplantation.

RISK OF HEPATOCELLULAR CARCINOMA

PBC is associated with a risk of hepatocellular carcinoma. Risk factors include: Older age, male sex, prior blood transfusions, advanced histologic stage, signs of cirrhosis and portal hypertension68.

PROGNOSIS

The Mayo Risk Score is widely used to predict survival in patients with PBC69. It takes into account age of the patient, total bilirubin, prothrombin time (PT), and presence or absence of edema69. Since most of the features of AMA-negative PBC are similar to those of classic PBC, the Mayo Risk Score can also be used in patients with AMA-negative PBC.

OVERLAP SYNDROMES

This term has recently been coined; it is used when two autoimmune pathologies co-exist in the same liver69,70. Overlap is seen between Autoimmune Hepatitis (AIH) / PBC, AIH / Chronic Hepatitis C, AIH / Crypto-genic Chronic Hepatitis, and AIH / Primary Sclerosing Cholangitis.

CONCLUSION

Primary Biliary Cirrhosis (PBC) is an important clinical entity. If AMA is negative by immunofluorescence, it needs to be repeated by ELISA or immunoblotting. If negative by any of these modalities as well, only then can it be labelled as AMA-negative PBC. Overlap syndromes need to be considered in patients diagnosed with PBC. In such cases steroids need to be added in the very start for the treatment of autoimmune hepatitis which is usually one of the autoimmune conditions in the syndrome.

REFERENCES

Primary biliary cirrhosis

Primary biliary cirrhosis


CONFLICT OF INTEREST: Authors declare no conflict of interest

GRANT SUPPORT AND FINANCIAL DISCLOSURE NIL

AUTHOR’S CONTRIBUTION

Following authors have made substantial contributions to the manuscript as under:

Badshah A: Compilation.
Haider I: Literature search.
Humayun M: References.

Authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.